Inactive Instrument

Cipher Pharmaceuticals Inc Stock Nasdaq

Equities

CA17253X1050

Pharmaceuticals

Sales 2024 * 28.87M 21.04M Sales 2025 * 29.33M 21.37M Capitalization 207M 151M
Net income 2024 * 12M 8.74M Net income 2025 * 13M 9.47M EV / Sales 2024 * 7.17 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 7.05 x
P/E ratio 2024 *
17.5 x
P/E ratio 2025 *
19.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.49%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 19-03-25
Director of Finance/CFO - 22-08-14
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 72 16-08-07
Director/Board Member 76 23-06-20
Chief Executive Officer - 19-03-25
More insiders
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.
More about the company